Om du la merke til at det stod or
4 Likes
Der ser jeg. Jeg tolker det som lipid nanoparticles benyttes til begge formål.
Edit: Ellers kanskje “naked” er cluet her. “Naked” kan ikke være med lipider eller?
Er kanskje der jeg blingser?
1 Like
Hvorfor skal du tolke det når du ser pipeline som sier naked mRNA in Melanoma vaccine? Project Code A001
1 Like
Offentliggjøring blir vel gjort i det avtaler inngås så jeg tviler på at det blir offentliggjort noen avtale på kommende konferanse.
6 Likes
Jeg er ikke fagkyndig men hvis jeg forstår det riktig så er LNP en egen leveransemekanisme enn naked mRNA. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453548/
3 Likes
Naked er levering uten vehicle som eksempelvis lipider
14 Likes
Riktig. Makes sense. My mistake!
Da er jo dette riktig så interessant!
4 Likes
Er vel hvordan man leser det. Er det ikke at de kan “enten” naked, eller LNP? Altså enten intranodally med naked mrna, eller intravonously med LNP. Dette er beskrivelse fra teknologien for melanoma hos etherna.
4 Likes
Enig, det holder mer enn nok med presentasjon av resultater om dette 
1 Like
Hva slags teknologi er dette da??
Preliminary experiments with a tumor-lytic modality showed impressive anti-tumor responses in the injected as well as in the non-injected tumors.
Måtte google lytic-
Kommer fra lysis som har følgende definisjon,
LY-sis) In biology, lysis refers to the breakdown of a cell caused by damage to its plasma (outer) membrane. It can be caused by chemical or physical means (for example, strong detergents or high-energy sound waves) or by infection with a strain virus that can lyse cells
Passer som hånd i hanske spør du meg. Lys i dette tilfellet.
29 Likes
@Investor Wow! 
. Det lukter gull .
Helt åpenlyst PCIB eller?
Takk for dine eminente vurderinger.
Jeg tar ingenting på forskudd og venter på fasit, men dette er en gledens dag. Såpass koster jeg på meg av en liten feiring! Spørsmålet er om en noengang kommer nærmere å kunne selge skinnet før bjørnen er skutt 
??
I biotek har jeg likevel lært at alt kan skje før det endelig er en fasit.
Sett mot verdivurderingen av PCIB nu likner det fortsatt på gravøl , 28,5kr eller en millliard i verdi?
Tydelig at mange har brent seg før (som eks AZ forventninger) og ikke lar seg rive med før hard facts/børsmelding. Forståelig. Og om så det kjøpes til noen ti kroner ++ eller dyrere så er vurdert risiko for mange da kraftig redusert. Mao verdt å vente på langt høyere kurs før en kjøper på hard facts? Vanskelig å vurdere riskreward. Men så sier de lærde at en skal få godt betalt for å ta høy risiko .
16 Likes
Data fra vaksinen skal komme dette året. Studiestart var 27.07.2017.
Skrevet 18.06.2020:
The company’s lead program, A001, is in Phase I/II tests to treat metastatic melanoma with data expected next year.
http://www.chinabiotoday.com/articles/etherna-raises-38-million
// 1 JUNE 2019
Safety and immune stimulation data from an intranodal delivery of TriMix mRNA, in the adjuvant melanoma study E011-MEL
Niel (Belgium)
eTheRNA immunotherapies NV (Niel, Belgium) announces that Dr. Ana Arance, Medical Oncologist at Hospital Clinic de Barcelona, will present safety and immune response data from the E011-MEL study at the ASCO (American Society of Clinical Oncology) Annual Meeting during the poster session “Developmental Immunotherapy and Tumor Immunobiology” on 01 June 2019. The study E011-MEL investigated the safety and immunogenicity of a mRNA-based immunotherapy ECI-006. ECI-006 is a combination of mRNAs encoding for the dendritic cell maturation triple mRNA TriMix together with mRNA coding for5 tumor-associated antigens, which aims to elicit an immune response against the tumor. Since the patients had been radically operated on, there was no expected, immediate clinical activity read-out.
The primary goal of the study was to study whether the injection of ECI-006 into inguinal or axillary lymph nodes was tolerable and clinically feasible. The intranodal injections were performed in the clinic under ultrasound guidance without anesthesia. There were two treatment arms, each of 10 patients. One group received a dose of 600 µg and the other a dose of 1800 µg per injection. The study was performed in centres in Belgium and Spain.
Nineteen out of 20 patients completed the treatment. One patient discontinued the study after 4 doses due to disease relapse. Administration of ECI-006 was well tolerated in all patients with no serious side effects. ELISPOT and intracellular cytokine staining were performed on T cells pre-stimulated in vitro for 10-12 days. Vaccine-induced immune responses were detected in 4/10 and 3/10 patients treated with the low and high dose, respectively.
Dr Arance commented “it is very encouraging that we see immune responses against most of the antigens used in the vaccine. Clinically this therapy was eminently well tolerated and feasible. Future studies should include patients with metastatic disease and test whether dosing with a concomitant check-point inhibitor can be additive”
Dr Bertil Lindmark, CMO of eTheRNA Immunotherapies stated “The study showed that intranodal therapy is clinically feasible and well tolerated. Specific Immune responses in 35% of the patients in the adjuvant setting gives a good basis for coming studies in metastatic melanoma on top of a checkpoint inhibitor”
13 Likes
Seems Ukraine is recruiting now 
42 Likes
Prøvde lengre oppe å få en forklaring på ‘Intranodal injection’ men det gikk ikke, ser nå det det blir injisert inn i en lymfe-node. Er vi sikker på att det er forenlig med Vacc belysning?
Fikk inntrykk av at lymfe-nodene ligger for dypt for belysning av den plaster-boksen?
Om denne leverings metoden er prøvd ut i 20 pasienter som beskrevet i @lenny 's siste post utelukker vel det FimaVacc?
Tumor-lytic som Investor beskrev virker mer lovende, men ser ikke ut som om de er kommet så langt med det?
Gleder meg veldig til presentasjonene neste uke men synes det blir litt mye haleluja nå. 
Edit: Så E011-MEL studien ett par poster over var uten FimaVacc, men de nevner videre studier med en CPI i tillegg, så da er det ingenting i veien for å bytte levering også går jeg ut fra.
Vanskelig for en lekmann å holde følge her, men mulig hype-toget har noe for seg likavel da. 
2 Likes
What a beautiful day
Ok, I’ll wake you up at ATH 
4 Likes
At these price levels I prefer to sleep 
please wake me up at 80NOK O’clock 
23 Likes
Fra utdrag fra fimaVacc patentet 21 januar 2020, som PW har uttalt klart og tydelig var et viktig patent for PCIB. Hvorfor det? Legg merke til ordet CYTOKINES
Oslo (Norway), 21 January 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has granted the company a US patent covering the use of fimaVacc in combination with cytokines.
The combination of cytokines with PCI Biotech’s vaccine technology, fimaVacc, has been shown to be effective for enhancing cellular immune responses that are important for the effect of therapeutic vaccines. The now granted US patent gives broad coverage for the combination of various cytokines with the fimaVacc technology.
Effective induction of cytotoxic T-cells will be critical to realise the huge potential of therapeutic cancer vaccines, but vaccines often fail to generate such responses. Insufficient delivery of vaccine antigens to the appropriate presentation pathway in the immune cells may be one of the main reasons for weak cytotoxic T-cell responses. The fimaVacc technology has the potential to effectively enhance vaccine presentation through these pathways.
Så til et poster fra eTheRNA sin NAKED MRNA Melanoma vaksine, som viser stort fokus på T-celle respons og C Y T O K I NE S:
Kan også laste ned PDF her:
Clinically this therapy was eminently well tolerated and feasible. Future studies should include patients with metastatic disease and test whether dosing with a concomitant check-point inhibitor can be additive”
Dr Bertil Lindmark, CMO of eTheRNA Immunotherapies stated “The study showed that intranodal therapy is clinically feasible and well tolerated. Specific Immune responses in 35% of the patients in the adjuvant setting gives a good basis for coming studies in metastatic melanoma on top of a checkpoint inhibitor”
Kilde: News | Archive 2019 | eTheRNA immunotherapies NV
Det begynner å bli mange fellesnevnere. Noe jeg har glemt?
- Samarbeid eTheRNA-PCIB siden 2016
- Naked mRna delivery
- Melanoma (patent fimaVacc granted)
- Patent fimaVacc cytokines januar 2020
- Fokus på T-celle respons (CD8) og cytokines i vaksine (se poster)
69 Likes
Takk for den fabelaktige jobben du gjør, Lenny.
16 Likes
Hva kan dette dreie seg om i verdier om det mye klaffer?